Vyne Therapeutics IncNASDAQ:VYNE
- LAST PRICE3.0300
- TODAY'S CHANGE (%)0.1300 (4.4828%)
- Bid / Lots2.7500/ 1
- Ask / Lots3.1800/ 1
- Open / Previous Close2.8800 / 2.9000
- Day Range
- 52 Week Range
- Volume67,653
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VYNE |
|---|---|---|
| 09:32 ET | 200 | 2.88 |
| 09:37 ET | 1000 | 2.88 |
| 09:44 ET | 100 | 2.96 |
| 09:46 ET | 500 | 2.9899 |
| 09:48 ET | 400 | 2.99 |
| 09:50 ET | 200 | 2.98 |
| 09:51 ET | 200 | 2.98 |
| 09:55 ET | 100 | 2.99 |
| 10:00 ET | 500 | 2.9465 |
| 10:02 ET | 1500 | 2.9003 |
| 10:04 ET | 500 | 2.9342 |
| 10:08 ET | 600 | 2.9438 |
| 10:09 ET | 300 | 2.99 |
| 10:15 ET | 100 | 2.99 |
| 10:18 ET | 1000 | 2.95 |
| 10:22 ET | 100 | 2.95 |
| 10:29 ET | 464 | 2.9313 |
| 10:33 ET | 400 | 2.92 |
| 10:38 ET | 237 | 2.9031 |
| 10:44 ET | 100 | 2.93 |
| 10:49 ET | 100 | 2.91 |
| 10:56 ET | 713 | 2.93 |
| 10:58 ET | 100 | 2.96 |
| 11:05 ET | 100 | 2.96 |
| 11:09 ET | 102 | 2.935 |
| 11:12 ET | 100 | 2.95 |
| 11:20 ET | 900 | 2.955 |
| 11:21 ET | 100 | 2.98 |
| 11:25 ET | 900 | 2.97 |
| 11:27 ET | 600 | 2.96 |
| 11:30 ET | 100 | 2.97 |
| 11:32 ET | 100 | 2.97 |
| 11:36 ET | 400 | 2.97 |
| 11:38 ET | 100 | 2.98 |
| 11:39 ET | 200 | 2.98 |
| 11:48 ET | 800 | 2.98 |
| 11:52 ET | 1400 | 2.96 |
| 11:54 ET | 100 | 2.98 |
| 11:56 ET | 1556 | 2.99 |
| 11:59 ET | 200 | 2.99 |
| 12:01 ET | 5929 | 3.02 |
| 12:03 ET | 913 | 3.0442 |
| 12:06 ET | 100 | 3.08 |
| 12:08 ET | 100 | 3.08 |
| 12:14 ET | 500 | 3.065 |
| 12:15 ET | 100 | 3.065 |
| 12:17 ET | 100 | 3.07 |
| 12:19 ET | 1057 | 3.1 |
| 12:24 ET | 333 | 3.105 |
| 12:26 ET | 3094 | 3.1 |
| 12:37 ET | 800 | 3.0689 |
| 12:50 ET | 210 | 3.08 |
| 12:55 ET | 300 | 3.09 |
| 12:57 ET | 100 | 3.09 |
| 01:09 ET | 100 | 3.1 |
| 01:11 ET | 510 | 3.1183 |
| 01:15 ET | 500 | 3.12 |
| 01:20 ET | 100 | 3.11 |
| 01:22 ET | 500 | 3.11 |
| 01:24 ET | 300 | 3.1 |
| 01:56 ET | 200 | 3.08 |
| 01:58 ET | 100 | 3.09 |
| 02:02 ET | 4000 | 3.0805 |
| 02:03 ET | 100 | 3.09 |
| 02:09 ET | 100 | 3.11 |
| 02:12 ET | 200 | 3.085 |
| 02:18 ET | 100 | 3.09 |
| 02:20 ET | 100 | 3.08 |
| 02:23 ET | 137 | 3.0791 |
| 02:43 ET | 100 | 3.08 |
| 02:52 ET | 200 | 3.075 |
| 02:57 ET | 4949 | 3.05 |
| 03:01 ET | 100 | 3.07 |
| 03:06 ET | 100 | 3.07 |
| 03:08 ET | 674 | 3.025 |
| 03:14 ET | 100 | 3.04 |
| 03:24 ET | 100 | 3.04 |
| 03:33 ET | 200 | 3.02 |
| 03:35 ET | 100 | 3.045 |
| 03:42 ET | 200 | 3.04 |
| 03:44 ET | 300 | 3.03 |
| 03:50 ET | 1457 | 3.04 |
| 03:51 ET | 733 | 3.03 |
| 03:57 ET | 100 | 3.06 |
| 04:00 ET | 12086 | 3.03 |
Nov 18, 2024
DJ Vyne Therapeutics Initiated at Buy by BTIG, from 8:49AM ET on Monday Nov 18, 2024 by Dow Jones
8:49AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 8, 2024
DJ Vyne Therapeutics Price Target Maintained With a $5.75/Share by HC Wainwright & Co., from 5:21AM ET on Friday Nov 08, 2024 by Dow Jones
5:21AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
8:00AM ET on Thursday Nov 07, 2024 by Dow Jones*DJ Vyne Therapeutics 3Q Loss $12.2M >VYNE, from 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vyne Therapeutics Inc | 44.7M | -3.6x | --- |
Serina Therapeutics Inc | 44.9M | -1.1x | --- |
Gain Therapeutics Inc | 44.7M | -1.5x | --- |
Actinium Pharmaceuticals Inc | 45.2M | -1.0x | --- |
OKYO Pharma Ltd | 35.5M | -1.5x | --- |
Achilles Therapeutics PLC | 43.6M | -0.6x | --- |
Company Information
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Contact Information
- Headquarters
- 685 Route 202/206 N., Suite 301BRIDGEWATER, NJ, United States 08807
- Phone
- 650-486-1416
- Fax
- 302-655-5049
Executives
- President, Chief Executive Officer, Director
- David Domzalski
- Chief Financial Officer, Treasurer
- Tyler Zeronda
- Chief Scientific Officer
- Iain Stuart
- Chief Legal Officer, General Counsel, Secretary
- Mutya Harsch
- Lead Independent Director
- Patrick Lepore
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $44.7M |
|---|---|
Revenue (TTM) | $493.0K |
Shares Outstanding | 14.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.38 |
EPS | $-0.85 |
Book Value | $6.29 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | 90.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -7,646.86% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
